Evidence map›Paper›PMID 26878656›Full record

Trial reportBone marrow transplantation2016

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.

M van Gelder, M H van Oers, W G Alemayehu, M C J Abrahamse-Testroote, J J Cornelissen, M E Chamuleau, P Zachée, M Hoogendoorn, M Nijland, E J Petersen and 6 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Collaboration ofFuture science OA · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 2 countries.

M van GelderDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
M H van OersDepartment of Hematology and Lymphoma and Myeloma Center, Academic Medical Center, Amsterdam, The Netherlands.
W G AlemayehuHOVON Data Center, Erasmus Medical Center, Rotterdam, The Netherlands.
M C J Abrahamse-TestrooteDepartment of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
J J CornelissenDepartment of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
M E ChamuleauDepartment of Hematology, Free University Medical Center, Amsterdam, The Netherlands.
P ZachéeDepartment of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerpen, Belgium.
M HoogendoornDepartment of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
M NijlandDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
E J PetersenDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
A BeekerDepartment of Internal Medicine, Spaarne Ziekenhuis, Hoofddorp, The Netherlands.
G-J TimmersDepartment of Internal Medicine, Ziekenhuis Amstelland, Amstelveen, The Netherlands.
L VerdonckDepartment of Internal Medicine, Isala Klinieken, Zwolle, The Netherlands.
M WestermanDepartment of Internal Medicine, Medisch Centrum Alkmaar, Alkmaar, The Netherlands.
O de WeerdtDepartment of Internal Medicine, Antonius ziekenhuis Nieuwegein, Nieuwegein, The Netherlands.
A P KaterDepartment of Hematology and Lymphoma and Myeloma Center, Academic Medical Center, Amsterdam, The Netherlands.
Academic Medical Center · NLErasmus MC · NLIsala · NLMaastricht University · NLMedisch Centrum Alkmaar · NLMedisch Centrum Leeuwarden · NLSpaarne Ziekenhuis · NLSt. Antonius Ziekenhuis · NLUniversity Medical Center Groningen · NLUniversity Medical Center Utrecht · NLZiekenhuis Amstelland · NLZiekenhuisnetwerk Antwerpen Stuivenberg · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) <1 year after fludarabine or <2 years after fludarabine-based immunochemotherapy or R/R with del(17p). Twenty-nine patients received ⩾3 cycles of R-DHAP and sixteen <3 cycles (4 because of disease progression, 8 for toxicity and 4 toxic deaths). Overall rate of response to R-DHAP was 58%, 31 (67%) proceeded to alloSCT after conditioning with fludarabine and 2 Gy TBI. Twenty (65%) remained free from progression at 2 years after alloSCT, including 17 without minimal residual disease. Intention-to-treat 2-year PFS and overall survival of the 46 patients were 42 and 51% (35.5 months median follow-up); del(17p) or fludarabine refractoriness had no impact. R-DHAP followed by alloSCT is a reasonable treatment to be considered for high-risk CLL patients without access or resistance to targeted therapies.

Indexed as

CisplatinDisease-Free SurvivalHematopoietic Stem Cell TransplantationHumansLeukemia, Lymphocytic, Chronic, B-CellMiddle AgedNeoplasm, ResidualRiskSurvival RateTransplantation ConditioningTreatment OutcomeCisplatin

Identifiers

PMID26878656
OpenAlexW2282100889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.